Patterns of Helicobacter pylori resistance to metronidazole, clarithormycin and amoxicillin in Saudi Arabia

Journal of Bacteriology and Virology

Volumn 38, Issue 4, 2008, Pages 173-178

  Marie, Mohammed Ali M ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Helicobacter pylori; Resistance; Treatment

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; METRONIDAZOLE;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; EPSILOMETER TEST; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SAUDI ARABIA; STOMACH BIOPSY;

HELICOBACTER PYLORI;

EID: 77953481716     PISSN: 15982467     EISSN: None     Source Type: Journal    
DOI: 10.4167/jbv.2008.38.4.173     Document Type: Article

References (31)

1. Ahmad MM, Rahman M, Rumi AK, Islam S, Huq F, Chowdhury MF, Jinnah F, Morshed MG, Hassan MS, Khan AK, Hasan M: Prevalence of Helicobacter pylori in asymptomatic population -a pilot serological study in Bangladesh. J Epidemiol 7: 251-254, 1997.
2. Alarcon T, Domingo D, Lopez-Brea M: Discrepencies between E-test and agar dilution methods for testing metronidazole susceptibility of Helicobacter pylori. J Clin Microbiol 36: 1165-1166, 1998.
3. al-Moagel MA, Evans DG, Abdulghani ME, Adam E, Evans DJ Jr, Malaty HM, Graham DY: Prevalence of Helicobacter (formerly Campylobacter) pylori infection in Saudia Arabia, and comparison of those with and without upper gastrointestinal symptoms. Am J Gastroenterol 85: 944-948,1990.
4. Axon AT: Helicobacterpylori therapy: effect on peptic ulcer disease. J Gastroenterol Hepatol6: 131-137, 1991.
5. Baker CN, Stocker SA, Culver DH, Thornsberry C: Comparison of the E test to agar dilution, broth microdilution, and agar diffusion susceptibility testing techniques by using a special challenge sobacteria. J Clin Microbiol 29: 533-538,1991.
6. Best LM, Haldane DJ, Bezanson GS, Veldhuyzen van Zanten SJ: Helicobacter pylori: primary susceptibility to clarithromycin in vitro in Nova Scotia. Can J Gastroenterolll: 298-300, 1997.
7. Cameron EA, Powell KU, Baldwin L, Jones P, Bell GD, Williams SG: Helicobacter pylori: antibiotic resistance and eradication rates in Suffolk, UK, 1991 -200 L J Med Microbiol 53: 535-538, 2004.
8. Cederbrant G, Kahlmeter G, Ljungh A: The E-test for antimicrobial susceptibility testing of Helicobacter pylori. J Antimicrob Chemother 31: 65-71, 1993.
9. Chaves S, Gadanho M, Tenreiro R, Cabrita J: Assessment.of metronidazole susceptibility in Helicobacterpylori: statisticalvalidation and error rate analysis of breakpoints determined by the disk diffusion test. J Clin Microbiol 37: 1628-1631, 1999.
10. Chida-Sakata N, Baba M, Inagawa H, Wada A, Tanaka T, Hosbihara Y, Takemoto T: Significance of anaerobic preincubation of Helicobacter pylori for measuring metronidazole susceptibility by the Etest. Microbiollmmunol 43: 397-401,1999.
11. de Wit NJ, Mendive J, Seifert B, Cardin F, Rubin G: Guidelines on the management of H pylori in primary care: development of an implementation strategy. Fam Pract 17: 827-S32, 2000.
12. Fallone CA, Barkun AN, Halwani E: Does Helicobacter pylori eradication prevent gastric cancer? Dig Liver Dis 33: 803-804,2001.
13. Fock KM: Peptic ulcer disease in the 1990s: an Asian perspective. J Gastroenter Hepatol 12: S23-S28, 1997.
14. Franzin L, Pennazio M, Cabodi D, Paolo RF, Gioannini P: Clarithromycin and amoxicillin susceptibility of Helicobacter pylori strains isolated from adult patients with gastric or duodenal ulcer in Italy. Curr Microbial 40: 96-100,2000.
15. Gisbert JP, Pajares JM: Helicobacter pylori rescue therapy after failure of two eradication treatments. Helicobacter 10: 363-372,2005.
16. Glupczynski Y, Labbe M, Hansen W, Crokaert F, Yourassowsky E: Evaluation of the E test for quantitative antimicrobial susceptibility testing of Helicobacterpylori. J Clin Microbial 29: 2072-2075, 1991.
17. Glupczynski Y, Megraud F, Lopez-brea M, Andersen LP: European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbial Infect Dis 20: 820-823, 2001.
18. Grignon B, Tankovic J, Megraud F, Glupczynski Y, Husson MO, Conroy MC, Emond JP, Loulergue J, Raymond J, Fauchere JL: Validation of diffusion methods for macrolide susceptibility testing of Helicobacterpylori. MicrobDrug Resist 8: 61-66, 2002.
19. Heep M, Kist M, Strobel S, Beck D, Lehn N: Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur J Clin Microbiol Infect Dis 19: 538-541,2000.
20. King A: Recommendations for susceptibility tests on fastidious organisms and those requiring special handling. J Antimicrob Chemother 48: 77-80, 2001.
21. Lind T, Megraud F, Unge P, Bayerdorffer E, O'marin C, Spiller R; Veldhuyzen Van Zanten S, Bardhan KD, Hellbiom M, Wrangstadb M, Zeijlon L, Cederberg C: The MACH2 study: Role of omeprazole in eradication of Helicobacter pylori with l-week triple therapies. Gastroenterology 116: 248-253,1999.
22. Megraud F, Lehn N, Lind T, Bayerddrffer E, O'Morain C, Spiller R, Unge P, Veldhuyzen van Zanten S, Wrangstadh M, Burman CF: Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study. Antimicrob Agents Chemother 43: 2747-2752,1999.
23. Meyer JM, Silliman NP, Wang W, Siepman NY, Sugg JE, Morris D, Zhang J, Bbattacharyya H, King EC, Hopkins RJ: Risk factors for Helicobacter pylori resistanceintheUnited States:the surveillance of H pylori antimicrobial resistance partnership (SHARP) study, 1993-1999. Ann Intern Med 136: 13-24, 2002.
24. Mohamed AE, al Karawi A, al Jumah A, Ahmed AM, Sharig S, Yasawy MI, Osaba O: Helicobacter pylori: incidence and comparison of three diagnostic methods in 196 Saudi patients with dyspepsia. Hepatogastroenterology 41: 48-50, 1994.
25. National Committee for Clinical Laboratory Standards (NCCLS): Performance standards for antimicrobial susceptibility testing: Eleventh Informational Supplement. National Committee for Clinical Laboratory Standards, Villanova, PA, 1999.
26. National Committee for Clinical Laboratory Standards (NCCLS): Performance standards for antimicrobial susceptibility testingandapprovedstandard M7-A5. Informational Supplement; MlOO-SlO.22. National Committee for Clinical Laboratory Standards, Wayne, PA, 2000.
27. Piccolomini R, Di Bonaventura G, Catamo G, Carbone F, Neri M: Comparative evaluation of the E test, agar dilution, and broth microdilution for testing susceptibilities of Helicobacter pylori strains to 20 antimicrobial agents. J Clin Microbiol 35: 1842-1846,
28. Torres J, Camorlinga-Ponce M, Perez-Perez G, Medrazo-De la Garza A, Dehesa M, GonzalezValencia G, Munoz O: Increasing multidrug resistance in Helicobacter pylori strains isolated from children and adults in Mexico. J Clin Microbiol 39: 2677-2680, 2001.
29. Utrup LJ, Flamm R, Osato M, Ferraro MJ, Reller LB, Barry A, Bush K, Silliman N: Susceptibility testing standardization and quality control ranges for Helicobacter pylori [abstract C-3l]. In Program and Abstracts of the 98th General Meeting of the American Society for Microbiology. American Society for Microbiology, Washington DC, 1998.
30. Wang G, Taylor DE: Site-specific mutations in the 23S rRNA gene of Helicobacterpylori confer two types of resistance to macrolide-lincosamide-streptogramin B antibiotics. Antimicrob Agents Chemother 42: 1952-1958, 1998.
31. Wolle K, Leodolter A, Malfertheiner P, Konig W: Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000. J Med Microbiol 51: 705-709, 2002.